Spark Investment Management LLC boosted its holdings in Esperion Therapeutics Inc (NASDAQ:ESPR) by 72.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 390,900 shares of the biopharmaceutical company’s stock after buying an additional 163,800 shares during the period. Spark Investment Management LLC’s holdings in Esperion Therapeutics were worth $15,694,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. State Board of Administration of Florida Retirement System increased its position in Esperion Therapeutics by 2.3% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 11,360 shares of the biopharmaceutical company’s stock worth $456,000 after buying an additional 260 shares during the period. Creative Planning increased its position in shares of Esperion Therapeutics by 3.8% during the fourth quarter. Creative Planning now owns 7,849 shares of the biopharmaceutical company’s stock valued at $361,000 after purchasing an additional 287 shares during the period. Advisor Group Inc. increased its position in shares of Esperion Therapeutics by 44.4% during the fourth quarter. Advisor Group Inc. now owns 947 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 291 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Esperion Therapeutics by 2.3% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 42,400 shares of the biopharmaceutical company’s stock valued at $1,950,000 after purchasing an additional 950 shares during the period. Finally, Parallel Advisors LLC bought a new stake in shares of Esperion Therapeutics during the first quarter valued at approximately $80,000.
A number of research firms have recently issued reports on ESPR. BidaskClub upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, May 9th. Credit Suisse Group boosted their price objective on Esperion Therapeutics from $79.00 to $90.00 and gave the company an “outperform” rating in a research report on Monday, May 6th. Bank of America upgraded Esperion Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Monday, May 6th. Cowen set a $94.00 price objective on Esperion Therapeutics and gave the company a “buy” rating in a research report on Sunday, May 5th. Finally, ValuEngine upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Esperion Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $75.45.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $3.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $2.43. The firm had revenue of $145.42 million for the quarter, compared to analyst estimates of $69.35 million. During the same period last year, the company earned ($1.73) EPS. As a group, equities analysts predict that Esperion Therapeutics Inc will post -2.09 EPS for the current fiscal year.
In other news, Director Nicole Vitullo sold 15,329 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $44.73, for a total transaction of $685,666.17. Following the transaction, the director now owns 8,319 shares of the company’s stock, valued at $372,108.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Roger S. Newton sold 25,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $50.06, for a total value of $1,251,500.00. Following the transaction, the director now directly owns 548,726 shares in the company, valued at approximately $27,469,223.56. The disclosure for this sale can be found here. In the last ninety days, insiders have bought 65,000 shares of company stock worth $3,155,550 and have sold 48,329 shares worth $2,280,206. Corporate insiders own 7.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Esperion Therapeutics Inc (ESPR) Holdings Lifted by Spark Investment Management LLC” was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/17/esperion-therapeutics-inc-espr-holdings-lifted-by-spark-investment-management-llc.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
See Also: What is a put option?
Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.